Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
PR Newswire Asia
SHANGHAI, March 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company..
SHANGHAI, March 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company..
Data readout from Phase 3 clinical trial in the People's Republic of China (“PRC”) evaluating F351 for the treatment of..
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Global Cell Counting Market: Analysis By Product, By Application, By End-User, By..